Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

2.

Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR.

J Neurosci. 2001 Dec 15;21(24):RC189.

3.

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease.

Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, Satyamurthy N, Barrio JR.

Mol Imaging Biol. 2003 Nov-Dec;5(6):404-17. Review.

PMID:
14667495
4.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
5.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.

PMID:
20385246
6.

Visualizing pathology deposits in the living brain of patients with Alzheimer's disease.

Kepe V, Huang SC, Small GW, Satyamurthy N, Barrio JR.

Methods Enzymol. 2006;412:144-60. Review.

PMID:
17046657
7.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR.

Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.

PMID:
11790632
8.

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Sep;50(9):1464-70. doi: 10.2967/jnumed.109.064360. Epub 2009 Aug 18.

9.

[Molecular imaging of beta-amyloid plaques in the brain].

Ono M.

Brain Nerve. 2007 Mar;59(3):233-40. Review. Japanese.

PMID:
17370649
10.

Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.

Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.

Nucl Med Biol. 2009 May;36(4):411-7. doi: 10.1016/j.nucmedbio.2009.01.013. Epub 2009 Mar 26.

PMID:
19423009
11.

Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain.

Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H, Yamamoto T, Staufenbiel M, Yanai K, Arai H, Sasaki H, Kudo Y, Sawada T.

J Neurosci. 2004 Mar 10;24(10):2535-41.

12.
13.

Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.

Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF.

Brain Res. 2004 Oct 29;1025(1-2):98-105. Erratum in: Brain Res. 2005 Jan 21;1031(2):302.

PMID:
15464749
14.

Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease.

Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, Karch R, Stanek J, Wolf T, Müller M, Langer O.

Mol Imaging Biol. 2009 Jul-Aug;11(4):236-40. doi: 10.1007/s11307-009-0198-z. Epub 2009 Feb 13.

PMID:
19214638
15.

Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro.

Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M.

J Neurosci. 2003 Sep 3;23(22):8029-33.

16.

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A.

J Biol Chem. 2005 Jun 24;280(25):23599-604. Epub 2005 Apr 26.

17.

Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.

Shin J, Lee SY, Kim SH, Kim YB, Cho SJ.

Neuroimage. 2008 Nov 1;43(2):236-44. doi: 10.1016/j.neuroimage.2008.07.022. Epub 2008 Jul 23.

PMID:
18694837
18.

Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.

Henriksen G, Yousefi BH, Drzezga A, Wester HJ.

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S75-81. doi: 10.1007/s00259-007-0705-x. Review.

PMID:
18224319
19.

[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR.

Neurobiol Dis. 2011 Sep;43(3):565-75. doi: 10.1016/j.nbd.2011.05.003. Epub 2011 May 13.

20.

PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB.

Eur J Nucl Med Mol Imaging. 2005 May;32(5):593-600. Epub 2005 Mar 25.

PMID:
15791432
Items per page

Supplemental Content

Write to the Help Desk